GenOway reports revenues of €10.9 million in the first half of 2026

genOway, a specialist in preclinical solutions, announced revenues of €10.9 million for the first half of 2026, representing a 10% increase compared to 2025. This increase is explained by the success of genOway Shanghai, which generated €2.4 million, and by a solid order book for Catalogue Models.

To support this growth, genOway has strengthened its international strategy, opening franchises in Canada and Australia, as well as a new subsidiary in Japan. In the United States and Europe, despite a challenging environment, business remains on a positive trend.

For the second half of the year, genOway forecasts growth exceeding 15%. With a revenue target of €50 million by 2028, the "Route50+data" strategy continues.